Researchers were able to apply a machine-learning computational model to arrange stem cells into different shapes. The holy grail of medical advancements is being able to create organs out of one’s own cells. But to do that researchers have to organize stem cells into predictable patterns, which has been quite a struggle. 3-D printing is one approach
A novel bioink can integrate living cells into 3D scaffolds at a speed of one meter per second, making it possible to study the spread of diseases and produce tailor-made tissue. 3D bioprinting has come a long way in recent years, with scientists using living tissue to print organs as complex as human skin. Researchers in
Google has gained access to a huge trove of US patient data – without the need to notify those patients – thanks to a deal with a major health firm. The scheme, dubbed Project Nightingale, was agreed with Ascension, which hopes to develop artificial intelligence tools for doctors. Google can access health records, names and
Liquid-in-liquid 3D printing was first presented in a BMW funded MIT project. Although the project initially seemed limited in scope the possibilities of 3D printing within a liquid medium opens new opportunities in terms of escaping gravitational pull and thus producing parts that require a more volumetric approach, such as biological structures and organs. As reported
Using organoid technology, adult epithelial stem cells can be expanded in vitro to generate self organizing 3D epithelial structures that closely recapitulate the architecture and cellular composition of the tissue of origin. Because of their strict dependence on Wnt ligands for survival and growth, intestinal organoids have become the tool of choice for in vitro
European regulations might be responsible for lower numbers of advanced therapy clinical trials running in the region when compared to the US and Asia. Europe has historically been a pioneer in advanced therapies, such as cell and gene therapy. Europe was the first region to approve a gene therapy, and it boasts the highest number
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has received Orphan Designations from the European Commission (EC) for paclitaxel and encequidar (“Oral Paclitaxel”) for the treatment of soft tissue sarcoma, following a positive opinion from the
Neuromuscular experts with the University of Miami Health System and the Miller School of Medicine will launch a Phase 1/2 clinical trial (NCT04146051) using the CAR-T drug, Descartes-08, to treat patients with generalized myasthenia gravis. Generalized myasthenia gravis (GMG) is a rare disease and a chronic autoimmune condition in which auto-antibodies attack specific proteins at the
In a bid to determine factors linked to the most debilitating forms of multiple sclerosis (MS), Johns Hopkins Medicine researchers say they have identified three so-called “complement system” genes that appear to play a role in MS-caused vision loss. The researchers were able to single out these genes — known to be integral in the
Purpose: The primary goal of the present study was to develop the nano-drug consisting of doxorubicin and exosome derived from mesenchymal stem cells, and to explore its effect on osteosarcoma in vitro. Methods: The exosomes were isolated from bone marrow MSCs (BM-MSCs) by an Exosome Isolation Kit. The exosome-loaded doxorubicin (Exo-Dox) was prepared by mixing
